cas 31181-90-5|| where to buy 5-bromopyridine-2-carbaldehyde

Product Name:5-bromopyridine-2-carbaldehyde

IUPAC Name:5-bromopyridine-2-carbaldehyde

Packing Unit	Available Stock	Price($)
CM104127-25g	in stock	ƥŗ
CM104127-100g	in stock	Ǫƥƈ
CM104127-500g	1-2 Weeks	ǙǙľǙ

For R&D use only.

Inquiry Form

Chemical Name

CAS Number

Quantity*

Required Specifications*
(Assay %, Material Grade etc.)

Contact Name*

Contact Email*

Additional Notes

Verification code*

refresh

: CAS NO:31181-90-5; Molecular Formula:C6H4BrNO; Melting Point:-; Smiles Code:[H]C(=O)C1=NC=C(Br)C=C1; Density:

: Catalog Number:CM104127; Molecular Weight:186.01; Boiling Point:237.7°C at 760 mmHg; MDL No:MFCD04112535; Storage:Keep in Inert atmosphere, store at 2-8°C.

: Pyridines; Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.; Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu; Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer; Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

: Camizestrant; Recently, Evaluate Pharma released an analysis report on the trends in the biopharmaceutical industry in 2024. The report mentioned 10 potential key R&D pipelines, including the small molecule drug camizestrant. Camizestrant is a next-generation oral SERD and pure Erα antagonist that has demonstrated anti-cancer activity across a range of preclinical models, including in patients with ER-activating mutations.